{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:02:59Z","timestamp":1792036979487,"version":"4.4.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jconrel.2024.10.057","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T11:32:51Z","timestamp":1730460771000},"page":"777-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Extracellular vesicles powered cancer immunotherapy: Targeted delivery of adenovirus-based cancer vaccine in humanized melanoma model"],"prefix":"10.1016","volume":"376","author":[{"given":"Sara","family":"Mathlouthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Kuryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Prygiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra Anna","family":"Zasada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Rinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Salmaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Garofalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.10.057_bb0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0010","series-title":"Prognosis of Patients with Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment","volume":"40","author":"Garbe","year":"2024"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0015","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/1758834017708160","article-title":"Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date","volume":"9","author":"Boespflug","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0020","article-title":"Molecular Frontiers in melanoma: pathogenesis, diagnosis, and therapeutic advances","volume":"25","author":"Kim","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0025","doi-asserted-by":"crossref","DOI":"10.1097\/PPO.0b013e31824ba4df","article-title":"Targeting NRAS in melanoma","volume":"18","author":"Kelleher","year":"2012","journal-title":"Cancer J."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0030","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.gendis.2022.04.004","article-title":"Melanoma: molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance","volume":"9","author":"Wagstaff","year":"2022","journal-title":"Genes Dis."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0035","first-page":"7277","article-title":"Revolutionizing cancer treatment: unleashing the power of viral vaccines, monoclonal antibodies, and proteolysis-targeting chimeras in the new era of immunotherapy","volume":"9","author":"Mohite","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0040","first-page":"1","article-title":"Cancer vaccines as promising immuno - therapeutics: platforms and current progress","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13025","article-title":"Peptide-based therapeutic cancer vaccine: current trends in clinical application","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1029069","article-title":"mRNA vaccines for cancer immunotherapy","volume":"13","author":"Vishweshwaraiah","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.923647","article-title":"Potentialities and challenges of mRNA vaccine in Cancer immunotherapy","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0060","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic viruses: newest frontier for cancer immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0075","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0080","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","article-title":"Oncolytic viruses as antigen-agnostic cancer vaccines","volume":"33","author":"Russell","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/v2010078","article-title":"Oncolytic viruses for cancer therapy: overcoming the obstacles","volume":"2","author":"Wong","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1308890","article-title":"Oncolytic virotherapy in cancer treatment: challenges and optimization prospects","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0100","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1038\/s41467-021-22929-z","article-title":"Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination","volume":"12","author":"Roy","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0105","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.tcb.2023.01.002","article-title":"Extracellular vesicles and nanoparticles: emerging complexities","volume":"33","author":"Jeppesen","year":"2023","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0110","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2018.05.015","article-title":"Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment","volume":"283","author":"Garofalo","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2018.12.022","article-title":"Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice","volume":"294","author":"Garofalo","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0120","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/v10100558","article-title":"Systemic administration and targeted delivery of immunogenic oncolytic adenovirus encapsulated in extracellular vesicles for cancer therapies","volume":"10","author":"Garofalo","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0125","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.7150\/thno.68667","article-title":"Surface-engineered extracellular vesicles for targeted delivery of therapeutic RNAs and peptides for cancer therapy","volume":"12","author":"Jayasinghe","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0130","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.7150\/jca.71992","article-title":"From immunosuppression to immunomodulation - turning cold tumours into hot","volume":"13","author":"Garofalo","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114300","article-title":"Priming with oncolytic adenovirus followed by anti-PD-1 and paclitaxel treatment leads to improved anti-cancer efficacy in the 3D TNBC model","volume":"199","author":"Kuryk","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0140","series-title":"Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model","first-page":"1","author":"Garofalo","year":"2021"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1259314","article-title":"Novel combinatorial therapy of oncolytic adenovirus AdV5\/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model","volume":"13","author":"Garofalo","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12895-017-0061-x","article-title":"Variation of mutant allele frequency in NRAS Q61 mutated melanomas","volume":"17","author":"H\u00e9lias-Rodzewicz","year":"2017","journal-title":"BMC Dermatol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0155","series-title":"Targeted Treatment of Advanced NRAS-Mutated Melanoma","first-page":"84616","volume":"8","author":"Koelblinger","year":"2017"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds257","article-title":"Melanoma as a model tumour for immuno-oncology","volume":"23","author":"Maio","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0165","series-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","author":"Levchenko","year":"2019"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.0493","article-title":"Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma","volume":"1","author":"Thomas","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114008","article-title":"A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma","volume":"202","author":"Wei","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112696","article-title":"Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response","volume":"42","author":"Randic","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0185","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0190","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ccell.2021.05.014","article-title":"Oncolytic virotherapy: potentially a game-changing tumor treatment","volume":"39","author":"Kessler","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00136","article-title":"Modulation of the intratumoral immune landscape by oncolytic herpes simplex virus virotherapy","volume":"7","author":"Yin","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2015.1105429","article-title":"Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma","volume":"5","author":"Capasso","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696791","article-title":"Beyond just peptide antigens: the complex world of peptide-based cancer vaccines","volume":"12","author":"Stephens","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0210","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.R120.002309","article-title":"The peptide vaccine of the future","volume":"20","author":"Nelde","year":"2021","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0215","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/jmv.25677","article-title":"Chimeric oncolytic Ad5\/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor","volume":"92","author":"Kuryk","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0220","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0225","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","article-title":"Peptide-based vaccines: current progress and future challenges","volume":"120","author":"Malonis","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0230","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00262-008-0493-6","article-title":"HLA typing demands for peptide-based anti-cancer vaccine","volume":"57","author":"Nagorsen","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0235","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/ijc.30228","article-title":"Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5\/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model","volume":"139","author":"Kuryk","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0240","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40883-023-00295-0","article-title":"Extracellular vesicles: a Trojan horse delivery method for systemic administration of oncolytic viruses","volume":"9","author":"Taheri","year":"2023","journal-title":"Regen. Eng. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0245","article-title":"Heterologous and cross-species tropism of cancer- derived extracellular vesicles","volume":"9","author":"Garofalo","year":"2019"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0250","doi-asserted-by":"crossref","DOI":"10.1080\/20013078.2020.1747206","article-title":"Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery","volume":"9","author":"Saari","year":"2020","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0260","doi-asserted-by":"crossref","first-page":"24641","DOI":"10.3402\/jev.v3.24641","article-title":"Routes and mechanisms of extracellular vesicle uptake","volume":"3","author":"Mulcahy","year":"2014","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0265","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41419-024-06494-z","article-title":"Roles of exosomes in immunotherapy for solid cancers","volume":"15","author":"Lyu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2024.10.057_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12085","article-title":"Biodistribution of extracellular vesicles following administration into animals: a systematic review","volume":"10","author":"Kang","year":"2021","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0275","series-title":"Current Understanding of Extracellular Vesicle Homing \/ Tropism","author":"Edelmann","year":"2022"},{"key":"10.1016\/j.jconrel.2024.10.057_bb0280","article-title":"Exosomes mediate intercellular transmission of porcine reproductive and respiratory syndrome virus","volume":"92","author":"Ting","year":"2018","journal-title":"J. Virol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924007314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924007314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T13:37:53Z","timestamp":1733578673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924007314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":55,"alternative-id":["S0168365924007314"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.10.057","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extracellular vesicles powered cancer immunotherapy: Targeted delivery of adenovirus-based cancer vaccine in humanized melanoma model","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.10.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}